SHOT has reported serious hazards of transfusion since 1996. This paper reviews some of the major complications related to transfusion such as transfusion-related acute lung injury, transfusion-associated circulatory overload, transfusion-associated dyspnoea and acute and haemolytic transfusion reactions. Both under-use and over-use of blood and blood components have been reported and the authors emphasise the importance of education in proper use of this resource. The optimal trigger for transfusion in the critically ill is still unknown.
Introduction
A UK-wide confidential reporting scheme for adverse events in transfusion was set up in 1996 (SHOT -Serious Hazards of Transfusion). SHOT, independent and professionally-led, was one of the first reporting systems to initiate haemovigilance in a systematic way. Data is collected continuously, analysed and published as an annual report (www.shotuk.org).
Initially reporting was voluntary, but is now a requirement of several agencies (Clinical Pathology Accreditation, Health Service Circular 2007/001 Better Blood Transfusion, Healthcare Standards and National Patient Safety Agency SPN14 [1] [2] [3] [4] ) with increasing participation over the years, to 98% of hospitals by 2011. Analysis of adverse events has resulted in changes to transfusion practice both in the sourcing of components (such as the use of male plasma for fresh frozen plasma (FFP)) and in attention to the clinical use of components and to patient safety. Although there are no denominator data, the incidents are benchmarked against the total number of blood components issued and hospitals are now sent information about their participation compared to institutions with similar blood component usage.
We review here the key features of the UK haemovigilance reporting to SHOT, with particular reference to those relevant to intensive care practice.
What issues have been uncovered for intensive care?
Great care must be taken to prevent errors, which make up about half of reports to SHOT. Some complications of transfusion may precipitate admission to the intensive care unit (ICU), particularly pulmonary symptoms, which have not always been recognised as resulting from transfusion. There have been generic and fundamental errors, such as failure to identify the correct patient at the point of blood sampling and failure to conduct the final administration check at the bedside. Inadequate checks occur particularly in emergency situations in the administration of blood and blood components. All these, disappointingly, can also occur in ICUs despite one-toone nursing care and a 24-hour medical presence. Adverse events may occur in patients who are already in the ICU following administration of blood components, but patients may also be admitted to ICU as a result of transfusion-related morbidity occurring on a general ward (eg collapse or renal failure due to ABO incompatibility, the development of transfusion-related acute lung injury (TRALI), or transfusionassociated circulatory overload (TACO)). A further important group of errors results from the failure to request appropriate components for patients with specific requirements, especially the unrecognised need for irradiated cellular products for individuals previously treated with immunosuppressive chemotherapy (particularly fludarabine) or who have had Hodgkin' s disease in the past but who are now admitted for another reason. Patients who have received haematopoietic stem cell transplants or solid organ transplants may also require irradiated components.
The principles that underlie the practice of transfusion in intensive care are well known. These include an appreciation of the physiology of oxygen delivery, coagulation pathways, and the need to correct pathological processes that potentially diminish global or microvascular oxygen delivery (shock, acute respiratory distress syndrome, sepsis and septic shock). In many cases red cell transfusion may be necessary to increase haemoglobin (Hb) concentration. However this has not always led to uniform practice as demonstrated in the seminal work done in Canada and Europe in the last two decades. 5, 6 can be caused by blood and blood component transfusion may manifest themselves in very non-specific pathophysiology that presents as organ failure (sometimes multiple organ failure). Three common precipitants leading to intensive care support may be triggered by blood transfusion. These are respiratory failure, cardiovascular collapse and acute renal failure.
Transfusion-related causes of respiratory failure
Pulmonary oedema is an under-recognised and potentially serious complication of blood transfusion. Distinct mechanisms include adverse immune reactions and circulatory overload. The former is associated with increased pulmonary vascular permeability and is commonly referred to as TRALI. The latter causes hydrostatic pulmonary oedema and is commonly referred to as TACO.
Transfusion-related acute lung injury (TRALI)
TRALI is defined as acute dyspnoea with hypoxia and bilateral pulmonary infiltrates during or within six hours of transfusion not due to circulatory overload or other likely causes. TRALI is caused by the presence of antibodies in the donor plasma that react with recipient leucocyte antigens causing lung damage. It can be difficult to be sure about the relationship between the transfusion and pulmonary symptoms, so that TRALI may be classified into the following imputability levels: • Highly likely -where there was a convincing clinical picture and positive serology • Probable -where there was either a less convincing history and positive serology or a good history and less convincing or absent serology • Possible -where either the clinical picture or serology was compatible with TRALI, but other causes could not be excluded • Unlikely -where the picture and serology were not supportive of the diagnosis. There were 27 TRALI cases described in all in the 2010 and 2011 SHOT reports. 4, 7 It should be noted that the number of proven cases of TRALI (ie where donor antibody and recipient antigen match) have decreased in the UK since the UK Blood Services implemented risk-reduction strategies in 2003/4 for TRALI, then the leading cause of transfusion-related mortality and major morbidity. These include the preferential use of male donors to provide FFP; male plasma for suspension of platelet pools; and preferential recruitment of male apheresis platelet donors and screening of female donors for HLA/HNA antibodies. These measures were implemented because the SHOT analysis demonstrated that TRALI was more likely to be associated with plasma components from female donors. Women who have been pregnant are known to have a higher incidence of HLA antibodies. These leucocyte antibodies activate neutrophils and they become trapped in the lung microvasculature with disruption of the integrity of the vessels, as enzymes and oxygen free radicals are released. This loss of structural integrity leads to capillary leakage and an increase in interstitial fluid, resulting in the classic chest X-ray appearance with widespread opacification, which is the hallmark of the condition.
It is worth noting that the distinction between hydrostatic (TACO) and permeability (TRALI) pulmonary oedema after transfusion is difficult, in part because the two conditions may coexist. The clinical and radiologic manifestations of TACO and TRALI are similar. Although echocardiography and B-type natriuretic peptide measurements may aid in the differential diagnosis between hydrostatic and permeability pulmonary oedema, invasive techniques such as right heart catheterisation and the sampling of alveolar fluid protein are sometimes necessary.
Transfusion-associated circulatory overload (TACO)
TACO is defined by the presence of any four of the following within six hours of transfusion:
• Acute respiratory distress • Tachycardia • Increased blood pressure • Acute or worsening pulmonary oedema • Evidence of positive fluid balance. TACO is potentially avoidable in many cases. Doctors should undertake pre-transfusion clinical assessment, taking into account concomitant medical conditions that increase the risk of TACO (cardiac failure, renal impairment, hypoalbuminaemia, fluid overload) and consider diuretic cover (eg frusemide).
In 2010, a total of 40 cases were reported to SHOT, and 70 in 2011. Eight deaths were recorded in which transfusion was implicated. There were 39 cases of major morbidity during 2010 and 2011, (defined by SHOT as the requirement for ICU admission and/or ventilation or new renal failure as a result of TACO). Most of these cases (36/39) required ICU/HDU admission or ventilation. Two of the remaining patients were already on ICU and required increased ventilator support after the development of TACO and the third required renal dialysis. Analysis of TACO cases showed the importance of the duration over which blood is transfused, with rapid transfusion in the absence of haemorrhage implicated. It is essential to monitor the rate of transfusion and fluid balance, as these factors influence the risk of a patient developing TACO.
TACO can occur after transfusion of a single unit of red cells or other components. Fresh frozen plasma is used too often and for uncertain indications. 8 Emergency warfarin reversal should be managed in accordance with guidelines 9,10 using prothrombin complex concentrates (PCC) where the volume of the therapeutic dose is small. FFP should not be used for this purpose. 9
Transfusion-associated dyspnoea (TAD)
TAD is characterised by respiratory distress developing within 24 hours of transfusion, which does not meet the diagnostic criteria for TRALI, TACO, or an allergic reaction. Respiratory distress in these cases is not explained by the patient' s underlying condition or any other known cause.
There were a total of 69 cases of TAD over the two-year reporting period 2010-2011, with nine of the 69 cases suffering major morbidity. There are considerable similarities and thus overlap in the presentations in this heterogeneous group of cases. Their unifying feature is respiratory distress. This group Review articles of patients is heterogeneous and will include patients with features of TACO, TRALI or ATR (acute transfusion reaction) and those with possible bacterial sepsis. However, they do not satisfactorily meet the criteria for any of these and cannot be easily explained by the patients' underlying medical conditions. Red cell transfusion is the most commonly implicated precipitant rather than transfusion with other components. The clinical picture will include some or all of these features: respiratory distress, tachycardia, hypertension, fever with a temperatures rise of more than 1.5°C, and rigours. TAD can occur as early as two hours post transfusion, which is within the six-hour window for TRALI.
TAD can occur up to 24 hours after transfusion. Appropriate investigations in suspected cases should include assessment of oxygen saturation (SpO 2 %, arterial blood gases) and a chest X-ray, as a minimum.
Cardiovascular collapse

Acute transfusion reactions (ATR)
ATR are defined as those occurring at any time up to 24 hours following a transfusion of blood components, excluding cases of acute reactions due to haemolysis or other defined causes such as those described above.
There has been a steady year-on-year increase in the number of cases reported, with 510 cases reported in 2010 and 587 in 2011. However, the number of severe reactions (anaphylaxis or severe allergic reactions) is stable, suggesting an increase in reporting of less severe episodes. It may be difficult to attribute the presenting symptoms to the transfusion, and other causes must be carefully excluded. New guidance has been published, with an algorithm and details of management. 11 The following symptoms are significant: fever, allergic reactions including anaphylaxis, urticaria, other rashes and hypotensive episodes, or a combination of these. The most frequently observed features are fever and allergic-type reactions. In the acute setting, whether on the ward or in ICU, the most important objective is to treat the symptoms whether or not the cause is clear. Anaphylaxis can occur with transfusion of any component, most commonly red cells and platelets. Anaphylaxis is treated with the administration of adrenaline, oxygen and fluids. 12 Steroids are often given, but evidence for their efficacy is lacking. Other presenting features of an allergic reaction include rigors, general malaise, and lumbar pain.
Hypotension without cardiovascular collapse may be the only feature. The following risk factors have been implicated: exposure of the blood to negatively charged filters, prostatic surgery, cardiac procedures involving cardiopulmonary bypass (due to release of cytokines and activation of the systemic inflammatory response syndrome), use of angiotensinconverting enzyme (ACE) inhibitors and patients with a defective kinin metabolism (those who present with a cough while on ACE inhibitors).
Haemolytic transfusion reactions (HTR)
These are caused by the breakdown of red cells by antibodies. They may occur acutely, as soon as blood is transfused, or several days later when the transfused blood has triggered an anamnestic antibody response.
Acute haemolytic reactions occur with symptoms/signs of haemolysis including fever within 24 hours of transfusion; haemolysis is confirmed by one or more of the following: a fall in Hb, a rise in lactate dehydrogenase (LDH), positive direct antiglobulin test (DAT), and a positive retrospective crossmatch. These reactions can occur if the patient has inadvertently been given the wrong unit due to error or because an antibody is present which was not detectable by the prior group and antibody screen, or crossmatch.
Delayed reactions occur more than 24 hours after transfusion and may be a week or more later, sometimes with similar clinical and laboratory features. Testing demonstrates the presence of one or more irregular antibodies which were not detectable pre-transfusion. These reactions are usually caused by red cell antigens on the donor cells which provoke an antibody response in the recipient, resulting in delayed destruction of the transfused cells.
The ICU physician should consider full investigation for an irregular red cell antibody in a patient who develops unexpected jaundice and/or anaemia soon after transfusion and discuss this with staff in the transfusion laboratory. It is particularly important for clinicians caring for patients with sickle cell syndromes to be aware that symptoms suggestive of a sickle cell crisis occurring up to 14 days post transfusion could be due to a delayed haemolytic transfusion reaction. These patients are particularly at risk of allo-immunisation with repeated red cell transfusions and samples should be sent for appropriate serological investigation. Deaths in sickle cell disease patients have been reported due to hyper-haemolysis, where haemolysis appears to be exacerbated by transfusion and Hb levels fall below pre-transfusion levels. The mechanism is not well understood and it may occur in association with true delayed haemolysis due to irregular antibodies or in association with infection. It is important that such patients are carefully and closely monitored in association with a haematologist.
Acute renal failure in the context of transfusion reactions
When acute renal failure results from an incompatible blood transfusion, it defines major morbidity. However, in the context of the severely ill intensive care patient, renal failure and the need for renal replacement therapy often is the final common pathway of many causes of multiple organ failure. In critically ill patients, the kidney is usually an innocent bystander whose function is disturbed by the systemic effects of a disease process remote from the kidney. In general, preservation of renal function is best achieved by restoring and maintaining normal organ perfusion, avoiding nephrotoxic drugs and instituting effective treatment for the primary disease process. It is important for the ICU physician to consider whether a recent transfusion has contributed to or caused renal dysfunction. The mechanism of the kidney injury involves thrombosis in the microvasculature and deposition of fragmented Hb in the distal renal tubules. This precipitation of the Hb elements leads to blockage of the tubules. The extent of the deposition is thus inversely related to urine flow. Hence, in managing the condition, diuresis is to be promoted by maintenance of adequate renal perfusion and by means of diuretics. The use of vasopressors may become necessary to achieve adequate perfusion and function, failing which renal replacement therapy may become inevitable.
Inappropriate and unnecessary or avoidable use of blood and blood products
These are defined by SHOT as transfusions given on the basis of erroneous, spurious or incorrectly documented laboratory testing results for Hb, platelets and coagulation tests, and transfusions given as a result of poor understanding and knowledge of transfusion medicine, such that the decision to transfuse puts the patient at significant risk or is actually harmful. It is important to note that several instances have been related to wrong Hb results obtained from blood gas analysers. These instruments should not be used for Hb estimation unless they have been properly quality-assured for this test. Spurious results frequently occur due to dilution when a blood sample is taken from a 'drip' arm or infusion line where the dead space has not been fully taken into account.
Under-transfusion, over-transfusion or delayed transfusion resulting in poorer patient outcome
The 2010 report highlighted inadequacy in the medical assessment and management of patients receiving blood transfusions with a number of themes emerging: • Lack of attention to fluid balance, particularly in elderly patients over 70 years and those with concomitant medical conditions that predispose to fluid overload, such as cardiac failure, renal impairment, hypoalbuminaemia and fluid overload. • Failure to consider that the rate of transfusion is another risk factor for the development of transfusion-associated circulatory overload. • There may be over-transfusion related to the assumption that one unit will raise the Hb by 1 g/dL in all adults, but this does not apply to patients of low body weight. The assumption can at best be only applied to a 70-80 kg patient and for patients of lower body weight, the prescription should be reduced. • There is a risk of over-transfusion in patients with minor but ongoing blood-loss. The amount of blood lost may be over-estimated and it is important to regularly monitor the Hb after every two or three units of red cells transfused. • Some prescribing errors are undoubtedly due to lack of knowledge of transfusion by doctors at all grades but additionally, doctors may be acting on insufficient information because of poor handover between shifts. The SHOT authors have identified a need to improve training about transfusion at all levels, undergraduate, post-graduate and in specialty training. A new education subgroup has been set up by the National Blood Transfusion Committee to assess the current training programmes and to make recommendations where necessary. • Delayed or under-transfusion incidents have been reported to SHOT and invariably, these involve at one level or another a lack of knowledge of how or when to activate the major haemorrhage protocol. Every hospital should have a major haemorrhage protocol that should be cascaded to all relevant members of staff in the appropriate clinical areas. These include accident and emergency, obstetrics and theatres. Although each hospital will have protocols tailored to their individual needs and circumstances, the overarching principle should be to simplify and expedite the process of acquiring large volumes of appropriate blood products and delivering them to the point of care. This may involve point-of-care testing, as well as drills to allow staff to practise and become familiar with the protocols. Most important in this is effective communication between all members of staff and this may only be achievable by there being designated communication co-ordinators in place. The NPSA (National Patient Safety Agency) issued guidance and published recommendations aimed at reducing delays in the provision of appropriate blood and blood components to patients in emergency situations. These are summarised in Table 1 .
Transfusion in intensive care
The Canadian Critical Care Trials Group' s Transfusion Requirements in Critical Care (TRICC) study reconfirmed the practice in ICU patients of permissible anaemia, because in this study, withholding transfusion providing the patient was stable, was not detrimental. 13 A positive benefit on survival was demonstrated when compared to a liberal transfusion strategy. The optimal treatment of anaemia in euvolaemic critically ill patients remains controversial. Despite the generous use of red cell transfusions in perioperative care, there is a paucity of evidence evaluating RBC transfusions in this setting, including intensive care. The TRICC study was published in 1999 and the study undertaken in the years prior to this. There has been a paradigm shift, with the acceptability of single unit blood transfusion and the lowering of transfusion triggers. Transfusion practice in intensive care, where transfusion triggers are more patientspecific and take into context underlying co-morbidities, remains a contentious area. 5 ICU populations are highly heterogeneous at multiple levels, including pre-illness comorbidity, diagnosis requiring admission, early illness severity, and subsequent complications. Dr Sakr and colleagues 14 report a single-centre cohort study evaluating the relationship between anaemia, blood transfusions and mortality in patients admitted to a surgical ICU. The authors report some findings that are not new or surprising. They report that anaemia is associated with adverse patient outcomes. However, when they performed multivariate analyses with adjustment for potential confounders to the blood transfusion/patient outcome relationship, they found that transfusions were associated with lower patient mortality, especially among older, sicker patients. At face value, this contradicts the majority of previous cohort studies 15 and the only large randomised trial of different transfusion triggers in critically ill patients (TRICC trial). 13 Dr Walsh' s findings raise a number of questions, including: does this association indicate cause and effect? Are the findings of the TRICC trial applicable to intensive care patients today? And, perhaps most importantly, should we use blood more liberally in critically ill patients than the TRICC trial and our current guidelines suggest? 16 A guideline has been published recently from the BCSH Transfusion Task Force which summarises the need for red cell transfusion in critically ill patients. 17
Conclusion
Improvements in safe transfusion practice have been achieved as a result of the increased awareness of blood safety issues and the initiatives and recommendations arising from analysis of the SHOT data. SHOT data have also provided evidence resulting in strategies that have improved the safety of the blood supply, such as the preferential use of male plasma donors by the Blood Services in 2003 to reduce the risk of TRALI and measures to reduce the risk of bacterial contamination of blood components. There has been a significant fall in bacterial infections from platelets in response to measures such as enhanced donor arm cleansing and diversion of the first portion of the donation.
In the 2010 SHOT report the authors noted an increased mortality and morbidity from TACO and over-transfusion. Although this partly represents improved awareness and reporting, it is clear that insufficient attention is often given to the medical assessment of patients prior to the transfusion, errors in prescribing continue, and there is often inadequate monitoring of response to transfusion. Cases reported to SHOT continue to highlight gaps in doctors' knowledge of transfusion medicine and the special requirements of their patients, problems of communication, especially around clinical handover and misinterpretation of laboratory results.
